SLC39A10
gene geneOn this page
Also known as KIAA1265FLJ90515DKFZp564L2123ZIP10
Summary
SLC39A10 (solute carrier family 39 member 10, HGNC:20861) is a protein-coding gene on chromosome 2q32.3, encoding Zinc transporter ZIP10 (Q9ULF5). Zinc-influx transporter. It is a selective cancer dependency (DepMap: 31.2% of cell lines).
Zinc is an essential cofactor for hundreds of enzymes. It is involved in protein, nucleic acid, carbohydrate, and lipid metabolism, as well as in the control of gene transcription, growth, development, and differentiation. SLC39A10 belongs to a subfamily of proteins that show structural characteristics of zinc transporters (Taylor and Nicholson, 2003 [PubMed 12659941]).
Source: NCBI Gene 57181 — RefSeq curated summary.
At a glance
- GWAS associations: 2
- Clinical variants (ClinVar): 97 total
- Cancer dependency (DepMap): dependent in 31.2% of screened cell lines
- MANE Select transcript:
NM_020342
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:20861 |
| Approved symbol | SLC39A10 |
| Name | solute carrier family 39 member 10 |
| Location | 2q32.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | KIAA1265, FLJ90515, DKFZp564L2123, ZIP10 |
| Ensembl gene | ENSG00000196950 |
| Ensembl biotype | protein_coding |
| OMIM | 608733 |
| Entrez | 57181 |
Gene structure
Transcript identifiers
Ensembl transcripts: 47 — 43 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 retained_intron
ENST00000359634, ENST00000409086, ENST00000412905, ENST00000418005, ENST00000430412, ENST00000444421, ENST00000458054, ENST00000464301, ENST00000465851, ENST00000867303, ENST00000867304, ENST00000867305, ENST00000867306, ENST00000867307, ENST00000867308, ENST00000919571, ENST00000919572, ENST00000919573, ENST00000919574, ENST00000919575, ENST00000919576, ENST00000919577, ENST00000919578, ENST00000919579, ENST00000919580, ENST00000919581, ENST00000919582, ENST00000919583, ENST00000919584, ENST00000919585, ENST00000919586, ENST00000919587, ENST00000919588, ENST00000919589, ENST00000919590, ENST00000919591, ENST00000919592, ENST00000919593, ENST00000919594, ENST00000919595, ENST00000919596, ENST00000919597, ENST00000919598, ENST00000919599, ENST00000956076, ENST00000956077, ENST00000956078
RefSeq mRNA: 2 — MANE Select: NM_020342
NM_001127257, NM_020342
CCDS: CCDS33353
Canonical transcript exons
ENST00000359634 — 10 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001400249 | 195680032 | 195681050 |
| ENSE00003556626 | 195718252 | 195718332 |
| ENSE00003560348 | 195706616 | 195706785 |
| ENSE00003560904 | 195708656 | 195708844 |
| ENSE00003603452 | 195683699 | 195683906 |
| ENSE00003645146 | 195728159 | 195728349 |
| ENSE00003665054 | 195713433 | 195713553 |
| ENSE00003671434 | 195716637 | 195717005 |
| ENSE00003848195 | 195734883 | 195737700 |
| ENSE00003850270 | 195657226 | 195657281 |
Expression profiles
Bgee: expression breadth ubiquitous, 248 present calls, max score 98.32.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 39.7450 / max 1377.9470, expressed in 1800 samples.
FANTOM5 promoters (13 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 24424 | 26.1322 | 1745 |
| 24425 | 6.9831 | 1607 |
| 24422 | 2.4409 | 982 |
| 24423 | 1.5920 | 758 |
| 24420 | 0.6948 | 298 |
| 24421 | 0.4153 | 188 |
| 24433 | 0.3058 | 130 |
| 24419 | 0.2723 | 125 |
| 24428 | 0.2615 | 87 |
| 24434 | 0.2304 | 95 |
Top tissues by expression
253 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| middle temporal gyrus | UBERON:0002771 | 98.32 | gold quality |
| secondary oocyte | CL:0000655 | 98.06 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 97.29 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 96.76 | gold quality |
| oocyte | CL:0000023 | 96.55 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 96.15 | gold quality |
| adrenal tissue | UBERON:0018303 | 95.57 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 95.49 | gold quality |
| postcentral gyrus | UBERON:0002581 | 95.38 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 95.15 | gold quality |
| parietal lobe | UBERON:0001872 | 94.91 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 94.49 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 94.45 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 94.41 | gold quality |
| prefrontal cortex | UBERON:0000451 | 94.16 | gold quality |
| thyroid gland | UBERON:0002046 | 94.13 | gold quality |
| ventricular zone | UBERON:0003053 | 93.93 | gold quality |
| frontal cortex | UBERON:0001870 | 93.65 | gold quality |
| entorhinal cortex | UBERON:0002728 | 93.54 | gold quality |
| ganglionic eminence | UBERON:0004023 | 93.28 | gold quality |
| neocortex | UBERON:0001950 | 93.26 | gold quality |
| cerebral cortex | UBERON:0000956 | 93.20 | gold quality |
| calcaneal tendon | UBERON:0003701 | 93.09 | gold quality |
| primary visual cortex | UBERON:0002436 | 92.93 | gold quality |
| occipital lobe | UBERON:0002021 | 92.36 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 91.91 | gold quality |
| parietal pleura | UBERON:0002400 | 91.56 | gold quality |
| stromal cell of endometrium | CL:0002255 | 91.54 | gold quality |
| right uterine tube | UBERON:0001302 | 91.43 | gold quality |
| temporal lobe | UBERON:0001871 | 91.40 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-137537 | yes | 6.41 |
| E-ANND-3 | yes | 4.35 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): MTF1, ZNF20
miRNA regulators (miRDB)
238 targeting SLC39A10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-3646 | 100.00 | 73.56 | 5283 |
| HSA-MIR-4692 | 100.00 | 67.32 | 2066 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-LET-7A-3P | 100.00 | 74.03 | 3932 |
| HSA-LET-7B-3P | 100.00 | 74.08 | 3913 |
| HSA-LET-7F-1-3P | 100.00 | 74.02 | 3928 |
| HSA-MIR-98-3P | 100.00 | 74.08 | 3907 |
| HSA-MIR-8485 | 100.00 | 77.57 | 4731 |
| HSA-MIR-30B-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30C-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-30A-5P | 100.00 | 76.31 | 3233 |
| HSA-MIR-30D-5P | 100.00 | 76.32 | 3233 |
| HSA-MIR-30E-5P | 100.00 | 76.32 | 3242 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-MIR-4514 | 99.99 | 67.10 | 1870 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-MIR-513B-5P | 99.99 | 69.96 | 2150 |
| HSA-MIR-8068 | 99.98 | 73.85 | 2376 |
| HSA-MIR-499A-5P | 99.98 | 70.79 | 1323 |
| HSA-MIR-6891-5P | 99.98 | 66.53 | 1372 |
| HSA-MIR-3148 | 99.97 | 75.06 | 6478 |
| HSA-MIR-3688-3P | 99.97 | 72.02 | 2834 |
| HSA-MIR-3065-5P | 99.97 | 71.56 | 3281 |
| HSA-MIR-4267 | 99.96 | 66.53 | 2368 |
| HSA-MIR-570-3P | 99.96 | 72.41 | 4910 |
| HSA-MIR-551B-5P | 99.96 | 71.28 | 3493 |
| HSA-MIR-4666A-3P | 99.96 | 71.71 | 3434 |
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 31.2% of screened cell lines.
Literature-anchored findings (GeneRIF, showing 10)
- Zinc and its transporters, ZIP6 and ZIP10, are required for the breast cancer cells motility stimulated with high glucose level, such as in diabetes. (PMID:24587242)
- A significant correlation between ZIP10 mRNA expressions with aggressiveness of RCC. (PMID:25200496)
- Slc39a10 plays a role in promoting the survival of macrophages through a Zn/p53-dependent axis in response to inflammatory stimuli. (PMID:29180421)
- ZIP10 is found in the proximal tubules collecting duct system and has a role in renal zinc transport. (PMID:30520657)
- Possible involvement of zinc transporter ZIP10 in atopic dermatitis. (PMID:31875492)
- The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosis. (PMID:32797246)
- ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway. (PMID:34706747)
- The bZIP transcription factor BATF3/ZIP-10 suppresses innate immunity by attenuating PMK-1/p38 signaling. (PMID:36409527)
- Functional characterization of SLC39 family members ZIP5 and ZIP10 in overexpressing HEK293 cells reveals selective copper transport activity. (PMID:36454509)
- SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways. (PMID:37524874)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | slc39a10 | ENSDARG00000005823 |
| mus_musculus | Slc39a10 | ENSMUSG00000025986 |
| rattus_norvegicus | Slc39a10 | ENSRNOG00000011677 |
| drosophila_melanogaster | foi | FBGN0024236 |
Paralogs (6): SLC39A14 (ENSG00000104635), SLC39A8 (ENSG00000138821), SLC39A5 (ENSG00000139540), SLC39A6 (ENSG00000141424), SLC39A4 (ENSG00000147804), SLC39A12 (ENSG00000148482)
Protein
Protein identifiers
Zinc transporter ZIP10 — Q9ULF5 (reviewed: Q9ULF5)
Alternative names: Solute carrier family 39 member 10, Zrt- and Irt-like protein 10
All UniProt accessions (5): C9J0F5, E7ENT5, E7EV45, F2Z341, Q9ULF5
UniProt curated annotations — full annotation on UniProt →
Function. Zinc-influx transporter. When associated with SLC39A6, the heterodimer formed by SLC39A10 and SLC39A6 mediates cellular zinc uptake to trigger cells to undergo epithelial-to-mesenchymal transition (EMT). SLC39A10-SLC39A6 heterodimers play also an essentiel role in initiating mitosis by importing zinc into cells to initiate a pathway resulting in the onset of mitosis. Plays an important for both mature B-cell maintenance and humoral immune responses. When associated with SLC39A10, the heterodimer controls NCAM1 phosphorylation and integration into focal adhesion complexes during EMT.
Subunit / interactions. Interacts with SLC39A6; which triggers cells to undergo EMT and mitosis. Found in a complex with SLC39A6, SLC39A10 and with the ‘Ser-727’ phosphorylated form of STAT3 throughout mitosis. Found in a complex with SLC39A6, SLC39A10 and with NCAM1; this complex controls NCAM1 phosphorylation and integration into focal adhesion complexes during epithelial-tomesenchymal transition. Found in a complex with SLC39A6, SLC39A10 and with GSK3B that controls NCAM1 phosphorylation.
Subcellular location. Cell membrane. Apical cell membrane.
Post-translational modifications. Undergoes N-terminal ectodomain shedding.
Induction. Up-regulated in several breast cancer lines, and correlated to cancer progression as a marker of metastatic breast cancer.
Similarity. Belongs to the ZIP transporter (TC 2.A.5) family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9ULF5-1 | 1 | yes |
| Q9ULF5-2 | 2 |
RefSeq proteins (2): NP_001120729, NP_065075* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR003689 | ZIP | Family |
| IPR050799 | ZIP_Transporter | Family |
Pfam: PF02535
Catalyzed reactions (Rhea), 1 shown:
- Zn(2+)(in) = Zn(2+)(out) (RHEA:29351)
UniProt features (29 total): compositionally biased region 8, transmembrane region 7, glycosylation site 4, modified residue 3, region of interest 2, signal peptide 1, chain 1, splice variant 1, sequence variant 1, sequence conflict 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9ULF5-F1 | 58.43 | 0.08 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (3): 536, 553, 591
Glycosylation sites (4): 139, 198, 218, 339
Function
Pathways and Gene Ontology
Reactome pathways
6 pathways
| ID | Pathway |
|---|---|
| R-HSA-442380 | Zinc influx into cells by the SLC39 gene family |
| R-HSA-382551 | Transport of small molecules |
| R-HSA-425366 | |
| R-HSA-425407 | SLC-mediated transmembrane transport |
| R-HSA-425410 | Metal ion SLC transporters |
| R-HSA-435354 | Zinc transporters |
MSigDB gene sets: 270 (showing top):
GSE45365_NK_CELL_VS_BCELL_UP, WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, GOBP_REGULATION_OF_B_CELL_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GGTGTGT_MIR329, MODULE_169, GOBP_REGULATION_OF_LEUKOCYTE_APOPTOTIC_PROCESS, GOBP_B_CELL_ACTIVATION, GOBP_TRANSITION_METAL_ION_TRANSPORT, GOBP_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_B_CELL_PROLIFERATION, GOBP_REGULATION_OF_LYMPHOCYTE_APOPTOTIC_PROCESS, ATGCAGT_MIR217
GO Biological Process (13): epithelial to mesenchymal transition (GO:0001837), negative regulation of B cell apoptotic process (GO:0002903), intracellular zinc ion homeostasis (GO:0006882), intracellular monoatomic cation homeostasis (GO:0030003), positive regulation of B cell proliferation (GO:0030890), positive regulation of B cell receptor signaling pathway (GO:0050861), zinc ion transmembrane transport (GO:0071577), zinc ion import across plasma membrane (GO:0071578), monoatomic ion transport (GO:0006811), zinc ion transport (GO:0006829), bicarbonate transport (GO:0015701), metal ion transport (GO:0030001), transmembrane transport (GO:0055085)
GO Molecular Function (5): zinc ion transmembrane transporter activity (GO:0005385), protein tyrosine phosphatase activator activity (GO:0008160), monoatomic cation:bicarbonate symporter activity (GO:0140410), protein binding (GO:0005515), metal ion transmembrane transporter activity (GO:0046873)
GO Cellular Component (3): plasma membrane (GO:0005886), apical plasma membrane (GO:0016324), membrane (GO:0016020)
Reactome top-level categories
Rollup of top-4 pathways:
| Category | Pathways |
|---|---|
| Zinc transporters | 1 |
| Transport of small molecules | 1 |
| SLC-mediated transmembrane transport | 1 |
| Metal ion SLC transporters | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| transport | 3 |
| zinc ion transmembrane transport | 2 |
| mesenchymal cell differentiation | 1 |
| B cell apoptotic process | 1 |
| regulation of B cell apoptotic process | 1 |
| negative regulation of lymphocyte apoptotic process | 1 |
| intracellular monoatomic cation homeostasis | 1 |
| inorganic ion homeostasis | 1 |
| intracellular monoatomic ion homeostasis | 1 |
| monoatomic cation homeostasis | 1 |
| regulation of B cell proliferation | 1 |
| B cell proliferation | 1 |
| positive regulation of lymphocyte proliferation | 1 |
| positive regulation of B cell activation | 1 |
| B cell receptor signaling pathway | 1 |
| regulation of B cell receptor signaling pathway | 1 |
| positive regulation of antigen receptor-mediated signaling pathway | 1 |
| zinc ion transport | 1 |
| monoatomic cation transmembrane transport | 1 |
| inorganic cation import across plasma membrane | 1 |
| transition metal ion transport | 1 |
| monoatomic cation transport | 1 |
| cellular process | 1 |
| transition metal ion transmembrane transporter activity | 1 |
| protein tyrosine phosphatase activity | 1 |
| protein phosphatase activator activity | 1 |
| bicarbonate transmembrane transporter activity | 1 |
| solute:monoatomic cation symporter activity | 1 |
| binding | 1 |
| monoatomic cation transmembrane transporter activity | 1 |
| metal ion transport | 1 |
| membrane | 1 |
| cell periphery | 1 |
| apical part of cell | 1 |
| plasma membrane region | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
828 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| SLC39A10 | SLC39A9 | Q9NUM3 | 808 |
| SLC39A10 | SLC30A1 | Q9Y6M5 | 804 |
| SLC39A10 | SLC39A1 | Q9NY26 | 794 |
| SLC39A10 | SLC39A11 | Q8N1S5 | 766 |
| SLC39A10 | SLC30A5 | Q8TAD4 | 753 |
| SLC39A10 | SLC30A4 | O14863 | 747 |
| SLC39A10 | SLC30A2 | Q9BRI3 | 733 |
| SLC39A10 | SLC30A6 | Q6NXT4 | 733 |
| SLC39A10 | SLC30A7 | Q8NEW0 | 731 |
| SLC39A10 | SLC30A9 | Q6PML9 | 714 |
| SLC39A10 | SLC39A6 | Q13433 | 684 |
| SLC39A10 | SLC30A10 | Q6XR72 | 670 |
| SLC39A10 | SLC30A3 | Q99726 | 640 |
| SLC39A10 | SLC39A3 | Q9BRY0 | 621 |
| SLC39A10 | SLC39A2 | Q9NP94 | 617 |
IntAct
113 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CFTR | ESYT2 | psi-mi:“MI:2364”(proximity) | 0.710 |
| LRRC32 | SMPD2 | psi-mi:“MI:0914”(association) | 0.640 |
| GPR156 | PLD2 | psi-mi:“MI:0914”(association) | 0.640 |
| SLC39A5 | TMEM223 | psi-mi:“MI:0914”(association) | 0.530 |
| LPAR1 | TMEM223 | psi-mi:“MI:0914”(association) | 0.530 |
| GYPB | TCAF2 | psi-mi:“MI:0914”(association) | 0.530 |
| SPINT2 | UPK3BL1 | psi-mi:“MI:0914”(association) | 0.530 |
| GALNT6 | NDUFS4 | psi-mi:“MI:0914”(association) | 0.530 |
| HTR2C | KLRG2 | psi-mi:“MI:0914”(association) | 0.530 |
| LGALS1 | PODXL | psi-mi:“MI:0914”(association) | 0.530 |
| LGALS1 | LAMA5 | psi-mi:“MI:0914”(association) | 0.530 |
| NRAS | ESYT2 | psi-mi:“MI:2364”(proximity) | 0.480 |
| NRN1L | SLC39A10 | psi-mi:“MI:0915”(physical association) | 0.400 |
| Bmpr1a | PLEKHG3 | psi-mi:“MI:0914”(association) | 0.350 |
| Cdca8 | NAP1L1 | psi-mi:“MI:0914”(association) | 0.350 |
| Smad3 | psi-mi:“MI:0914”(association) | 0.350 | |
| Cul1 | GPS1 | psi-mi:“MI:0914”(association) | 0.350 |
| Tnks | SDC2 | psi-mi:“MI:0914”(association) | 0.350 |
| Ncaph | ATP5MF-PTCD1 | psi-mi:“MI:0914”(association) | 0.350 |
| Aff1 | UVRAG | psi-mi:“MI:0914”(association) | 0.350 |
| TCF20 | MTA3 | psi-mi:“MI:0914”(association) | 0.350 |
| KIF18A | NCOR1 | psi-mi:“MI:0914”(association) | 0.350 |
| KIF7 | TBC1D31 | psi-mi:“MI:0914”(association) | 0.350 |
| MYC | TARS3 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (285): SLC39A10 (Affinity Capture-MS), SLC39A10 (Affinity Capture-MS), SLC39A10 (Affinity Capture-MS), SLC39A10 (Proximity Label-MS), SLC39A10 (Proximity Label-MS), SLC39A10 (Proximity Label-MS), SLC39A10 (Affinity Capture-MS), SLC39A10 (Affinity Capture-MS), SLC39A10 (Affinity Capture-MS), SLC39A10 (Affinity Capture-MS), SLC39A10 (Affinity Capture-MS), SLC39A10 (Affinity Capture-MS), SLC39A10 (Affinity Capture-MS), SLC39A10 (Affinity Capture-MS), SLC39A10 (Affinity Capture-MS)
ESM2 similar proteins: A0A0G2KQY6, A0A6I8PMZ8, A0JPN2, A4IGY6, A5D7L5, E9PU17, E9PX95, F1QYC4, F1S5L4, O35119, O60353, O62852, O94402, O95477, P0DX17, P41233, Q08E40, Q13433, Q15043, Q3SZN3, Q3TT99, Q4V887, Q504Y0, Q5FVQ0, Q5FWH7, Q5GJ77, Q5R9M9, Q5RAB7, Q5RCN4, Q61089, Q61586, Q6L8F3, Q6P5F6, Q6PEH9, Q6R5J1, Q6W3E5, Q75N73, Q84M24, Q8C145, Q8WMU5
Diamond homologs: A0A0G2KQY6, A0A6I8PMZ8, A4IGY6, A5D7H1, A5D7L5, A8WMY3, A8X482, L5KLU7, P0DX17, Q06916, Q15043, Q1KZG0, Q29175, Q2M1K6, Q31125, Q504Y0, Q5FVQ0, Q5FWH7, Q5R6I6, Q5RAB7, Q5RFD5, Q5TJF6, Q6L8F3, Q6MGB4, Q6P5F6, Q6PEH9, Q75N73, Q78IQ7, Q8AW42, Q8BZH0, Q91W10, Q92504, Q96H72, Q9C0K1, Q9M647, Q9PUB8, Q9ULF5, Q9UT11, Q9V3A4, Q9XTQ7
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 169 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Lysosphingolipid and LPA receptors | 5 | 36.6× | 1e-04 |
| DAP12 signaling | 5 | 17.7× | 5e-04 |
| Signaling by SCF-KIT | 5 | 11.9× | 2e-03 |
| Class A/1 (Rhodopsin-like receptors) | 10 | 7.1× | 2e-04 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 7 | 5.9× | 4e-03 |
| GPCR ligand binding | 9 | 5.5× | 1e-03 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| G protein-coupled receptor signaling pathway | 15 | 3.8× | 5e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
97 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 75 |
| Likely benign | 9 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2414 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 2:195681047:TGAA:T | donor_gain | 1.0000 |
| 2:195681048:GAA:G | donor_gain | 1.0000 |
| 2:195681048:GAAG:G | donor_gain | 1.0000 |
| 2:195681049:AA:A | donor_gain | 1.0000 |
| 2:195681050:AG:A | donor_loss | 1.0000 |
| 2:195681051:G:GG | donor_gain | 1.0000 |
| 2:195681052:TAAG:T | donor_loss | 1.0000 |
| 2:195683697:A:AG | acceptor_gain | 1.0000 |
| 2:195683698:G:GG | acceptor_gain | 1.0000 |
| 2:195683698:GT:G | acceptor_gain | 1.0000 |
| 2:195683902:ATCAG:A | donor_loss | 1.0000 |
| 2:195683904:CAGGT:C | donor_loss | 1.0000 |
| 2:195683905:AGGT:A | donor_loss | 1.0000 |
| 2:195683906:GGT:G | donor_loss | 1.0000 |
| 2:195683907:GT:G | donor_loss | 1.0000 |
| 2:195683908:T:G | donor_loss | 1.0000 |
| 2:195706614:A:AG | acceptor_gain | 1.0000 |
| 2:195706615:G:GG | acceptor_gain | 1.0000 |
| 2:195706782:CCAT:C | donor_gain | 1.0000 |
| 2:195706784:ATG:A | donor_loss | 1.0000 |
| 2:195706785:TGTA:T | donor_loss | 1.0000 |
| 2:195706786:G:C | donor_loss | 1.0000 |
| 2:195706786:G:GG | donor_gain | 1.0000 |
| 2:195706787:T:A | donor_loss | 1.0000 |
| 2:195708654:A:AG | acceptor_gain | 1.0000 |
| 2:195708655:G:GT | acceptor_gain | 1.0000 |
| 2:195708655:GTCT:G | acceptor_gain | 1.0000 |
| 2:195708655:GTCTC:G | acceptor_gain | 1.0000 |
| 2:195708841:AAGA:A | donor_gain | 1.0000 |
| 2:195708841:AAGAG:A | donor_loss | 1.0000 |
AlphaMissense
5619 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 2:195706651:A:C | S418R | 1.000 |
| 2:195706653:C:A | S418R | 1.000 |
| 2:195706653:C:G | S418R | 1.000 |
| 2:195706669:G:C | G424R | 1.000 |
| 2:195706744:G:A | G449R | 1.000 |
| 2:195706744:G:C | G449R | 1.000 |
| 2:195706745:G:A | G449E | 1.000 |
| 2:195706753:A:C | S452R | 1.000 |
| 2:195706755:T:A | S452R | 1.000 |
| 2:195706755:T:G | S452R | 1.000 |
| 2:195706756:G:A | G453R | 1.000 |
| 2:195706756:G:C | G453R | 1.000 |
| 2:195706757:G:A | G453E | 1.000 |
| 2:195706759:G:C | D454H | 1.000 |
| 2:195706760:A:T | D454V | 1.000 |
| 2:195706769:T:C | L457P | 1.000 |
| 2:195706771:C:G | H458D | 1.000 |
| 2:195706775:T:A | L459Q | 1.000 |
| 2:195706775:T:C | L459P | 1.000 |
| 2:195716949:C:A | A670D | 1.000 |
| 2:195716966:G:A | G676R | 1.000 |
| 2:195716966:G:C | G676R | 1.000 |
| 2:195716966:G:T | G676W | 1.000 |
| 2:195716969:G:C | D677H | 1.000 |
| 2:195716970:A:C | D677A | 1.000 |
| 2:195716970:A:G | D677G | 1.000 |
| 2:195716970:A:T | D677V | 1.000 |
| 2:195716971:T:A | D677E | 1.000 |
| 2:195716971:T:G | D677E | 1.000 |
| 2:195716972:G:C | G678R | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000055529 (2:195635958 A>G), RS1000056204 (2:195688254 A>C), RS1000087578 (2:195645398 T>C), RS1000143479 (2:195721701 A>C), RS1000164284 (2:195732103 T>C,G), RS1000198366 (2:195639006 A>G), RS1000270523 (2:195638742 G>A), RS1000279244 (2:195682049 C>T), RS1000324939 (2:195682065 A>T), RS1000351017 (2:195669023 C>G,T), RS1000356383 (2:195611340 A>G), RS1000383675 (2:195735219 G>C), RS1000437953 (2:195724848 G>A), RS1000463541 (2:195675538 C>G), RS1000483394 (2:195633328 G>A)
Disease associations
OMIM: gene MIM:608733 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
2 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST001531_4 | Temperament | 6.000000e-06 |
| GCST002790_3 | Food allergy | 5.000000e-06 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004825 | temperament and character inventory |
| EFO:0007016 | food allergy measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
GtoPdb / IUPHAR curated pharmacology
(IUPHAR/BPS Guide to Pharmacology — expert-curated)
Target class: transporter — SLC39 family of metal ion transporters
CTD chemical–gene interactions
71 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Air Pollutants | affects cotreatment, increases abundance, increases oxidation, affects expression, decreases expression | 4 |
| Cyclosporine | decreases expression | 4 |
| sodium arsenite | increases abundance, decreases expression | 3 |
| Benzo(a)pyrene | affects methylation, increases expression | 3 |
| Estradiol | affects cotreatment, increases expression, decreases expression | 3 |
| Valproic Acid | affects expression, decreases expression, decreases methylation | 3 |
| Zinc | increases transport, affects cotreatment, decreases expression, increases expression | 3 |
| bisphenol A | decreases expression | 2 |
| perfluorooctane sulfonic acid | decreases expression | 2 |
| Cadmium | decreases expression, increases response to substance, increases abundance | 2 |
| Ozone | increases abundance, affects expression, affects cotreatment, increases oxidation | 2 |
| Phenylmercuric Acetate | affects cotreatment, decreases expression | 2 |
| Aflatoxin B1 | affects expression, increases expression | 2 |
| Cadmium Chloride | decreases expression, increases abundance | 2 |
| p-Chloromercuribenzoic Acid | affects cotreatment, decreases expression | 2 |
| Particulate Matter | decreases expression, increases abundance | 2 |
| afuresertib | decreases expression | 1 |
| FR900359 | affects phosphorylation | 1 |
| ginger extract | increases abundance, decreases expression | 1 |
| dicrotophos | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| alpha-pinene | affects cotreatment, increases oxidation, increases abundance | 1 |
| arsenite | affects binding, decreases reaction | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| ochratoxin A | affects cotreatment, decreases expression | 1 |
| potassium chromate(VI) | decreases expression, affects cotreatment | 1 |
| coumarin | increases phosphorylation | 1 |
| methacrylaldehyde | affects cotreatment, increases oxidation, increases abundance | 1 |
| N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine | affects cotreatment, decreases expression | 1 |
| beta-methylcholine | affects expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.